NM_025137.4:c.7115T>A
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1_StrongPM2PP3_ModeratePP5_Very_Strong
The NM_025137.4(SPG11):c.7115T>A(p.Leu2372*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000198 in 1,613,900 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. L2372L) has been classified as Likely benign.
Frequency
Consequence
NM_025137.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 11Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Illumina, G2P
- amyotrophic lateral sclerosis type 5Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Charcot-Marie-Tooth disease axonal type 2XInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp
- juvenile amyotrophic lateral sclerosisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SPG11 | NM_025137.4 | c.7115T>A | p.Leu2372* | stop_gained | Exon 39 of 40 | ENST00000261866.12 | NP_079413.3 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SPG11 | ENST00000261866.12 | c.7115T>A | p.Leu2372* | stop_gained | Exon 39 of 40 | 1 | NM_025137.4 | ENSP00000261866.7 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152220Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251086 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.0000212 AC: 31AN: 1461680Hom.: 0 Cov.: 31 AF XY: 0.0000193 AC XY: 14AN XY: 727162 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152220Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74360 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Pathogenic:1
PM2_moderate, PM3_strong, PVS1_moderate -
Hereditary spastic paraplegia 11 Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SPG11 protein in which other variant(s) (p.His2388Thrfs*6) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 216009). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 27217339). This variant is present in population databases (rs762984907, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Leu2372*) in the SPG11 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 72 amino acid(s) of the SPG11 protein. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at